Nice and no doubt it will probably have some efficacy for simple cancers with a single antigen, or even a few. But it’s not personalized, so more complex cases probably will require more individualized and personalized treatments. Plus, CAR-T has been very expensive. But I would not be surprised if it helps for simpler cancers.
At least I initially. The additional challenge for car-t, where it does succeed, is with cancers that recur.
Market Data 
Markets 
AI
